PROSTATE CANCER SCREENING USING THE PROSTATE-SPECIFIC ANTIGEN (PSA) TEST
Journal: International Journal of Advanced Research (Vol.11, No. 6)Publication Date: 2023-07-01
Abstract
We aimed to conduct a systematic review and meta-analysis on published literature extracted from PubMed/Medline, Google scholar, and Cochrane library. The results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a statistically significant 29% prostate cancer mortality reduction for the men screened in the intervention arm and a 23% negative impact on the life-years gained because of quality of life. However, alternative prostate-specific antigen (PSA) screening strategies for the population may exist, optimizing the effects on mortality reduction, quality of life, over diagnosis, and costs.
Other Latest Articles
- Psychosocial outcome following kidney donation: A single-center experience
- Is the risk for COVID-19 outcomes the same for all patients with chronic kidney disease? A retrospective study
- STEM CELLS IN REGENERATIVE MEDICINE AND THERAPEUTIC POTENTIAL
- TURNING ART INTO VISION: PROSE, POETRY, PAINTING INTERFACE OF LANDSCAPE ARTISTS, AND IMPRESSIONISTS
- INFLUENCE OF MUSIC PREFERENCES ON ANGER LEVELS AMONG COLLEGE STUDENTS: AN ANALYTICAL STUDY
Last modified: 2023-07-31 19:38:29